基于影像组学预测TERT突变型高级别胶质瘤复发的研究进展

doi:10.3969/j.issn.1004-583X.2026.02.014

摘要/Abstract

摘要：

高级别胶质瘤(high-grade glioma, HGG)是中枢神经系统最具侵袭性的恶性肿瘤之一,其复发率高,患者预后极差。端粒酶逆转录酶(telomerase reverse transcriptase, TERT)基因启动子突变是HGG,尤其是胶质母细胞瘤(glioblastoma multiforme, GBM)的关键分子事件,与肿瘤的无限增殖、治疗抵抗及早期复发密切相关。在影像学方面,TERT 突变常引起胶质瘤的大小、形状、边界和信号强度等影像学特征的显著改变。传统的TERT突变检测依赖于有创的组织活检,且难以克服肿瘤的时空异质性。影像组学作为一种新兴的无创技术,能够从常规磁共振成像(MRI)中高通量提取定量特征,深度解码肿瘤内部的异质性。近年来,大量研究致力于构建基于影像组学的模型,以实现对HGG 的TERT突变状态的无创预测,并进一步将其应用于复发风险评估,为HGG的个体化精准管理提供了新方向。本文旨在综述TERT突变的临床意义,阐述影像组学的工作流程,重点讨论基于多参数MRI的影像组学在预测TERT突变及关联复发风险方面的最新研究进展,并分析当前挑战与未来发展方向。

关键词: 高级别胶质瘤, 端粒酶逆转录酶, 基因突变, 影像组学, 肿瘤复发, 磁共振成像, 预后预测

中图分类号:

古丽米热·依力哈木, 姜春晖, 王俭. 基于影像组学预测TERT突变型高级别胶质瘤复发的研究进展[J]. 临床荟萃, 2026, 41(2): 178-182.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.02.014

https://www.lchc.cn/CN/Y2026/V41/I2/178

参考文献 30

[1]	Sill M, Schrimpf D, Patel A, et al. Advancing CNS tumor diagnostics with expanded DNA methylation-based classification[J]. Cancer cell, 2025, 12(4):S1535- 6108(25)00495-7. doi:10.1016/j.ccell.2025.11.002.
[2]	Price M, Ballard CAP, Benedetti JR, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022[J]. Neuro Oncol, 2025, 27 (4): iv1-iv66. doi:10.1093/neuonc/noaf194.
[3]	Jiang T, Tang GF, Lin Y, et al. Prevalence estimates for primary brain tumors in China: A multi-center cross-sectional study[J]. Chin Med J, 2011, 124(17):2578-2583.
[4]	Jang B, Yoon D, Lee J, et al. Integrative multi-omics characterization reveals sex differences in glioblastoma[J]. Biol Sex Differ, 2024, 15(1):23. doi: 10.1186/s13293-024-00601-7. pmid: 38491408
[5]	Karipidis K, Baaken D, Loney T, et al. The effect of exposure to radiofrequency fields on cancer risk in the general and working population: A systematic review of human observational studies - Part I: Most researched outcomes.[J]. Environ Int, 2024, 191: 108983. doi: 10.1016/j.envint.2024.108983.
[6]	加潇坤, 彭冲奇, 赵振宇, 等. 脑胶质瘤 WHO 中枢神经系统肿瘤分类(第五版)分析: 附60例报告[J]. 中国现代神经疾病杂志, 2022, 22(12): 1086-1093.doi:10.3969/j.issn.1672-6731.2022.12.014.
[7]	Kannan S, Murugan AK, Balasubramanian S, et al. Gliomas: Genetic alterations, mechanisms of metastasis, recurrence, drug resistance, and recent trends in molecular therapeutic options[J]. Biochem Pharmacol, 2022, 201:115090. doi: 10.1016/j.bcp.2022.115090.
[8]	利华, 张晓华. 脑胶质瘤免疫治疗现状及进展[J]. 肿瘤, 2024, 44(9):963-970. doi: 10.3781/j.issn.1000-7431.2024.2401-0004.
[9]	Saueressig C, Delbridge C, Scholz D, et al. From histology to diagnosis: Leveraging pathology foundation models for glioma classification[J]. Comput Biol Med, 2025, 197(Pt A):110988. doi: 10.1016/j.compbiomed.2025.110988.
[10]	Horbinski C, Solomon DA, Lukas RV, et al. Molecular testing for the world health organization classification of central nervous system tumors: A review[J]. JAMA Oncol, 2025, 11(3):317-328.doi: 10.1001/jamaoncol.2024.5506.
[11]	Huang DS, Wang Z, He XJ, et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation[J]. Eur J Cancer, 2015, 51(8):969-976. doi: 10.1016/j.ejca.2015.03.010.
[12]	Di Nunno V, Aprile M, Bartolini S, et al. The biological and clinical role of the telomerase reverse transcriptase gene in glioblastoma: A potential therapeutic target?[J]. Cells, 2023, 13(1):44. doi: 10.3390/cells13010044.
[13]	Muralidharan K, Yekula A, Small JL, et al. TERT promoter mutation analysis for blood-based diagnosis and monitoring of gliomas[J]. Clin Cancer Res, 2021, 27(1):169-178.doi: 10.1158/1078-0432.CCR-20-3083. pmid: 33051308
[14]	Leone A, Di Napoli V, Fochi NP, et al. Virtual biopsy for the prediction of MGMT promoter methylation in gliomas: A comprehensive review of radiomics and deep learning approaches applied to MRI[J]. Diagnostics (Basel), 2025, 15(3):251. doi: 10.3390/diagnostics15030251.
[15]	Abdusalomov A, Umirzakova S, Bekmirzaev O, et al. From anatomy to genomics using a multi-task deep learning approach for comprehensive glioma profiling[J]. Bioengineering (Basel), 2025, 12(9):979. doi: 10.3390/bioengineering12090979.
[16]	Varela E, Blasco MA. 2009 nobel prize in physiology or medicine: Telomeres and telomerase[J]. Oncogene, 2010, 29(11):1561-1565. doi: 10.1038/onc.2010.15.
[17]	Shankar GM, Francis JM, Rinne ML, et al. Rapid intraoperative molecular characterization of glioma[J]. JAMA Oncol, 2015, 1(5):662-667. doi: 10.1001/jamaoncol.2015.0917. pmid: 26181761
[18]	张科平, 许洁, 林丹义, 等. TERT 启动子突变检测在胶质瘤中的意义[J]. 诊断病理学杂志, 2022, 29(7): 628-630, 634. doi:10.3969/j.issn.1007-8096.2022.07.013.
[19]	Vuong HG, Altibi AMA, Duong UNP, et al. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data[J]. Crit Rev Oncol Hematol, 2017, 120:1-9. doi: 10.1016/j.critrevonc.2017.09.013. pmid: 29198322
[20]	McAleenan A, Kelly C, Spiga F, et al. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide[J]. Cochrane Database Syst Rev, 2021, 3(3):CD013316. doi: 10.1002/14651858.CD013316.pub2.
[21]	Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis[J]. Eur J Cancer, 2012, 48(4):441-446. doi: 10.1016/j.ejca.2011.11.036. pmid: 22257792
[22]	Mayerhoefer ME, Materka A, Langs G, et al. Introduction to radiomics[J]. J Nucl Med, 2020, 61(4):488-495. doi: 10.2967/jnumed.118.222893.
[23]	Zhang H, Zhou B, Zhang H, et al. Peritumoral radiomics for identification of telomerase reverse transcriptase promoter mutation in patients with glioblastoma based on preoperative MRI[J]. Can Assoc Radiol J, 2024, 75(1):143-152. doi: 10.1177/08465371231183309.
[24]	Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype[J]. Cancer Res, 2017, 77(21):e104-e107. doi: 10.1158/0008-5472.CAN-17-0339.
[25]	Gerardi RM, Cannella R, Bonosi L, et al. Forecasting molecular features in IDH-Wildtype gliomas: The state of the art of radiomics applied to neurosurgery[J]. Cancers (Basel), 2023, 15(3):940. doi: 10.3390/cancers15030940.
[26]	Tang C, Chen L, Xu Y, et al. Prediction of TERT mutation status in gliomas using conventional MRI radiogenomic features[J]. Front Neurol, 2024, 15:1439598. doi: 10.3389/fneur.2024.1439598.
[27]	Li Y, Chen L, Huang L, et al. A radiomics-based nomogram may be useful for predicting telomerase reverse transcriptase promoter mutation status in adult glioblastoma[J]. Brain Behav, 2024, 14(5):e3528. doi: 10.1002/brb3.3528. pmid: 38798094
[28]	Zhang H, Zhang H, Zhang Y, et al. Deep learning radiomics for the assessment of telomerase reverse transcriptase promoter mutation status in patients with glioblastoma using multiparametric MRI[J]. J Magn Reson Imaging, 2023, 58(5):1441-1451. doi: 10.1002/jmri.28671. pmid: 36896953
[29]	Calabrese E, Rudie JD, Rauschecker AM, et al. Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma[J]. Neurooncol Adv, 2022, 4(1):vdac060. doi: 10.1093/noajnl/vdac060.
[30]	Chen L, Chen R, Li T, et al. MRI radiomics model for predicting TERT promoter mutation status in glioblastoma[J]. Brain Behav, 2023, 13(12):e3324. doi: 10.1002/brb3.3324. pmid: 38054695